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Abstract: BACKGROUND Rivaroxaban 2.5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100
mg reduced the risk of cardiovascular events as compared with ASA monotherapy in the COMPASS trial
(Cardiovascular Outcomes for People Using Anticoagulation Strategies) but increased the risk of major
bleedings. Analysis of net clinical benefit (NCB) is of key clinical relevance and represents an integrated
measure of overall patient outcome. METHODS The current prespecified analysis was performed to
assess the NCB of adding rivaroxaban 2.5 mg twice daily to ASA monotherapy in patients with chronic
vascular disease in the COMPASS study cohort (intention-to-treat study population), with a specific
focus on high-risk subgroups. The predefined NCB outcome was the composite of cardiovascular death,
stroke, myocardial infarction, fatal bleeding, or symptomatic bleeding into a critical organ. RESULTS
A lower number of NCB adverse outcomes was observed with rivaroxaban 2.5 mg twice daily plus ASA
versus ASA alone (hazard ratio, 0.80 [95% CI, 0.70-0.91], P=0.0005), which became increasingly favorable
with longer treatment duration. The main drivers of NCB outcomes were ”efficacy” events, in particular
stroke (0.5%/y versus 0.8%/y; hazard ratio, 0.58 [95% CI, 0.44-0.76], P<0.0001) and cardiovascular death
(0.9%/y versus 1.2%/y; hazard ratio, 0.78 [95% CI, 0.64-0.96], P=0.02), whereas the bleeding components
of the NCB, in particular fatal bleeding (0.09%/y versus 0.06%/y; hazard ratio, 1.49 [95% CI 0.67-3.33],
P=0.32), only represented a minority of NCB events. In selected high-risk subgroups, including patients
with polyvascular disease (฀2 vascular beds affected with atherosclerosis), impaired renal function, heart
failure, and/or diabetes mellitus, a larger absolute risk reduction for experiencing a NCB event was
observed. CONCLUSIONS Compared with ASA monotherapy, the combination of rivaroxaban 2.5 mg
twice daily plus ASA resulted in fewer NCB events primarily by preventing adverse efficacy events,
particularly stroke and cardiovascular mortality, whereas severe bleedings were less frequent and with
less clinical impact. The NCB was particularly favorable in high-risk subgroups and those with multiple
risk characteristics. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01776424.
DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.046048
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BACKGROUND: Rivaroxaban 2.5 mg twice daily plus acetylsalicylic 
acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular events as 
compared with ASA monotherapy in the COMPASS trial (Cardiovascular 
Outcomes for People Using Anticoagulation Strategies) but increased the 
risk of major bleedings. Analysis of net clinical benefit (NCB) is of key clinical 
relevance and represents an integrated measure of overall patient outcome.
METHODS: The current prespecified analysis was performed to assess 
the NCB of adding rivaroxaban 2.5 mg twice daily to ASA monotherapy 
in patients with chronic vascular disease in the COMPASS study cohort 
(intention-to-treat study population), with a specific focus on high-
risk subgroups. The predefined NCB outcome was the composite of 
cardiovascular death, stroke, myocardial infarction, fatal bleeding, or 
symptomatic bleeding into a critical organ.
RESULTS: A lower number of NCB adverse outcomes was observed 
with rivaroxaban 2.5 mg twice daily plus ASA versus ASA alone (hazard 
ratio, 0.80 [95% CI, 0.70–0.91], P=0.0005), which became increasingly 
favorable with longer treatment duration. The main drivers of NCB 
outcomes were “efficacy” events, in particular stroke (0.5%/y versus 
0.8%/y; hazard ratio, 0.58 [95% CI, 0.44–0.76], P<0.0001) and 
cardiovascular death (0.9%/y versus 1.2%/y; hazard ratio, 0.78 [95% 
CI, 0.64–0.96], P=0.02), whereas the bleeding components of the NCB, 
in particular fatal bleeding (0.09%/y versus 0.06%/y; hazard ratio, 1.49 
[95% CI 0.67–3.33], P=0.32), only represented a minority of NCB events. 
In selected high-risk subgroups, including patients with polyvascular 
disease (≥2 vascular beds affected with atherosclerosis), impaired renal 
function, heart failure, and/or diabetes mellitus, a larger absolute risk 
reduction for experiencing a NCB event was observed.
CONCLUSIONS: Compared with ASA monotherapy, the combination of 
rivaroxaban 2.5 mg twice daily plus ASA resulted in fewer NCB events 
primarily by preventing adverse efficacy events, particularly stroke and 
cardiovascular mortality, whereas severe bleedings were less frequent and 
with less clinical impact. The NCB was particularly favorable in high-risk 
subgroups and those with multiple risk characteristics.
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atients with chronic coronary syndromes or pe-
ripheral artery disease (PAD) remain at an in-
creased risk of cardiovascular events over the 
long term.1 The COMPASS trial (Cardiovascular Out-
comes for People Using Anticoagulation Strategies) 
demonstrated that in patients with chronic coronary 
syndromes and/or PAD, the combination of rivaroxa-
ban 2.5 mg twice daily plus acetylsalicylic acid (aspi-
rin) (ASA) 100 mg reduced the risk of cardiovascular 
events as compared with ASA monotherapy, albeit 
at an increased risk of major bleeding.2 Rivaroxaban 
5 mg twice daily versus ASA did not significantly re-
duce the primary outcome.
In clinical practice it may be difficult to weigh 
a reduction in ischemic events against an increase 
in bleeding events. For such practical purposes, the 
net clinical benefit (NCB) may constitute a better 
representation of the “net clinical value” of a novel 
treatment strategy, incorporating the most severe ef-
ficacy and safety events into 1 metric. By doing so, 
the NCB represents a more comprehensive measure 
of overall patient outcome rather than separately fo-
cusing on single events such as myocardial infarction 
(MI), stroke, or major bleeding. Indeed, patients with 
chronic vascular disease are frequently at risk of both 
severe ischemic and bleeding events, which both need 
to be taken into account to evaluate the value of an 
additional antithrombotic therapy.
The current prespecified analysis was therefore 
performed to assess the NCB of the combination of 
rivaroxaban 2.5 mg twice daily plus ASA versus ASA 
monotherapy in patients with chronic vascular disease 
in the overall COMPASS study cohort and in selected 
high-risk subgroups.
METHODS
Trial Design and End Points
The design and primary outcomes of the COMPASS trial 
have previously been published.2,3 Requests for data access 
will be considered by the COMPASS Publications Committee 
on an individual basis beginning 4 years after publication of 
the main results.2 In brief, COMPASS was a double-blind, 
multicenter, randomized clinical trial that enrolled 27 395 
high-risk patients with a clinical history of coronary and/or 
PAD, comparing ASA alone (with rivaroxaban placebo) to the 
combination of rivaroxaban 2.5 mg twice daily and ASA, or 
rivaroxaban 5 mg twice daily (with ASA placebo). The study 
was approved by an institutional review board at each site, 
and all participants gave informed consent before study pro-
cedures. The antithrombotic comparisons in the trial were 
stopped early after a mean follow-up of 23 months because 
of clear benefit of rivaroxaban 2.5 mg twice daily plus ASA 
over ASA alone; we therefore limited our current analysis to 
this trial population (n = 18 278).
The primary efficacy outcome of COMPASS was a com-
bination of cardiovascular death, stroke, or MI; the principal 
safety end point was major bleeding according to modified 
International Society on Thrombosis and Haemostasis (ISTH) 
criteria, including fatal bleeding, symptomatic bleeding into 
a critical organ, bleeding into a surgical site requiring reop-
eration, and bleeding that led to hospitalization (including 
presentation to an acute care facility without an overnight 
stay). The predefined NCB outcome, based on previous anti-
coagulation trials,4,5 was the composite of cardiovascular 
death, stroke, MI, fatal bleeding, or symptomatic bleeding 
into a critical organ (including intraarticular, intramuscular 
with compartment syndrome, intraspinal, intracranial, intra-
ocular, respiratory, pericardial, liver, pancreas, retroperito-
neal, adrenal gland or kidney; or bleeding into the surgical 
site requiring reoperation).2
NCB Analysis
We analyzed the occurrence of NCB events in the overall 
study cohort and in previously identified high-risk sub-
groups of the COMPASS population, including patients 
with polyvascular disease (≥2 vascular beds affected with 
atherosclerosis), impaired renal function (estimated glo-
merular filtration rate ≤60 mL/min), heart failure, diabetes 
mellitus, or a combination of these risk characteristics.5 We 
also analyzed the NCB in patients <65 years of age (in such 
patients the study mandated for the presence of additional 
risk factors) and ≥65 years of age.6,7
Clinical Perspective
What Is New?
• Compared with acetylsalicylic acid (aspirin) mono-
therapy, the combination of rivaroxaban 2.5 mg 
twice daily plus aspirin resulted in fewer net clinical 
benefit events primarily by preventing adverse effi-
cacy events, particularly stroke and cardiovascular 
mortality, whereas severe bleedings were less fre-
quent and had less clinical impact.
• The net clinical benefit was particularly favorable 
in high-risk subgroups and those with multiple risk 
characteristics.
What Are the Clinical Implications?
• “Net clinical benefit” represents an easy to use 
integrative measure of overall patient benefit in 
daily clinical practice by combining efficacy and 
safety outcomes of important clinical relevance (ie, 
myocardial infarction, stroke, cardiovascular death, 
life-threatening and fatal bleedings).
• Use of the predefined net clinical benefit of adding 
rivaroxaban 2.5 mg twice daily to aspirin demon-
strates fewer serious adverse events.
• Our data may hence help clinicians and patients in 
their shared decision-making process of choosing 
the optimal antithrombotic therapy.
• This is particularly true for high-risk patients, who 
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All analyses were conducted in the intention-to-treat 
study population. Baseline characteristics are presented as 
mean±SD for continuous variables and frequencies for cate-
gorical variables. Baseline characteristics were compared with 
the Wilcoxon rank sum tests for continuous variables and χ2 
tests for categorical variables. Survival analyses were based on 
the time to a first event. Event rates were expressed per 100 
patient-years of follow-up. Stratified Cox proportional haz-
ards regression models were used to estimate hazard ratios 
(HR) and corresponding 95% CIs to compare the effects of 
rivaroxaban plus ASA versus ASA alone in selected high-risk 
subgroups. Significance was tested using stratified log-rank 
tests. The assumption of the proportional hazards was veri-
fied using the plots of log of the negative log of survival func-
tion against the log of time. Absolute risk reduction (ARR) was 
calculated as the difference between Kaplan-Meier cumula-
tive risks of an outcome in rivaroxaban 2.5 mg twice daily 
plus ASA and ASA alone treatment groups at 12, 24, and 30 
months of follow-up. ARR is expressed as events prevented/
caused per 1000 patients treated. There was no correction for 
multiple comparisons. All tests were 2-sided with a P value 
<0.05 considered to be significant. Analyses were conducted 




Characteristics of patients experiencing versus not ex-
periencing a NCB event are shown in Table 1. As an-
ticipated, baseline characteristics of patients differed 
in non-high-risk versus high-risk subgroups, which 
included age <65 years (plus additional risk factors), 
atherosclerotic manifestation in ≥2 vascular beds, renal 
insufficiency, heart failure, and diabetes mellitus in that 
patients in high-risk subgroups demonstrated a higher 
prevalence of risk factors and comorbidities.7
NCB in the Overall COMPASS Population
Significantly fewer NCB adverse outcomes were ob-
served with rivaroxaban 2.5 mg twice a day plus ASA 
versus ASA alone (HR, 0.80 [95% CI, 0.70–0.91], 
P=0.0005; Figure 1, Table 2).2 The contribution of the 
individual NCB components is shown in Figure 2. The 
main drivers of NCB outcomes were “efficacy” events, 
in particular stroke and cardiovascular death. In con-
trast, the bleeding components of the NCB, in particu-
lar fatal bleeding, only represented a small proportion 
of NCB events (without any significant differences be-
tween the 2 randomized groups). Sensitivity analyses 
counting only ST-elevation and new Q-wave MIs yield-
ed similar results (NCB HR, 0.76 [95% CI, 0.66–0.88]; 
P=0.0002). In contrast, replacing life-threatening and 
fatal bleeding events with all major bleeding events ac-
cording to the modified ISTH definition resulted in no 
detectable difference in NCB outcomes between the 2 
study groups (HR, 0.99 [95% CI, 0.89–1.11], P=0.91) 
because of inclusion of a large number of less severe 
bleeding events.
Separation of the Kaplan-Meier curves occurred 
early, with a further divergence during trial progression 
(Figure  2A) indicating an increasing NCB with longer 
treatment duration (ARR per 1000 patients treated, 
rivaroxaban 2.5 mg twice daily plus ASA versus ASA, 
–3.9 [95% CI, –8.7 to 0.8], –13.9 [95% CI, –21.4 to 
–6.5], and –19.5 [95% CI, –28.9 to –10.0], after 12, 
24, and 30 months, respectively). As such, the number 
of prevented “efficacy” NCB events increased, whereas 
the number of “safety” NCB events remained constant 
(and low) over time (Figure 2B).
NCB in Selected High-Risk Populations
The NCBs in selected high-risk subgroups are shown in 
Figure 3 and Figure 4. Kaplan-Meier curves of high-risk 
patients separated earlier and more markedly than for 
the overall population and continued to separate over 
time, in favor of rivaroxaban 2.5 mg twice daily plus 
ASA (Figure 3).
We did not observe any significant interaction in 
the relative impact of the combination of rivaroxaban 
plus ASA versus ASA alone in any of the high-risk sub-
groups. Similar HRs were observed for the respective 
high-risk groups, and in each instance, a lower HR was 
observed in the presence of the high-risk feature com-
pared with the absence of this feature (Figure 4). In the 
nonprespecified subanalysis of patients ≥75 years, a di-
rectionally similar result was seen, which was, however, 
not significant because of the smaller sample size and 
resulting lack of statistical power (Table I in the Data 
Supplement).
Because patients in these high-risk subgroups had a 
substantially higher absolute risk, they derived a larger 
ARR from the combination of rivaroxaban plus ASA, 
and this resulted in an even lower number needed to 
treat (NNT). As an example, patients with estimated glo-
merular filtration rate <60 mL/min had a 3.8%/y event 
rate with rivaroxaban plus ASA as compared with 4.8% 
with ASA alone (HR, 0.79 [95% CI, 0.64–0.98]); in con-
trast, patients with estimated glomerular filtration rate 
≥60 mL/min had an event rate of 2.1%/y and 2.6%/y 
with rivaroxaban plus ASA and ASA alone, respectively 
(HR, 0.81 [95% CI, 0.69–0.94], P interaction=0.89). 
The higher absolute event rate in patients with estimat-
ed glomerular filtration rate <60 mL/min led to a higher 
ARR (3.3% versus 1.5%) and, as a result, a lower NNT 
(31 versus 67 over 30 months).
The contributions of the individual components of 
the NCB in high-risk versus non-high-risk subgroups 
are shown in Table I in the Data Supplement. In line 
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drivers of NCB outcomes were “efficacy” events, par-
ticularly in the high-risk subgroups, with lower rates for 
bleeding into a critical organ and markedly lower inci-
dences in fatal bleeding.
Impact of Additional Risk Factors
The impact of additional risk factors had an additive 
effect in augmenting the ARR and reducing the NNT 
(Figure 4). When all 4 selected high-risk features were 
present (polyvascular, renal dysfunction, heart failure, 
and diabetes mellitus), an ARR of 3.37%/y and a NNT 
of 9 patients/30 mo was observed. For those with 3 
high-risk features, the NNT at 30 months was 12, and 
for those with 2 high-risk features, it was 31 (Figure 4). 
In contrast, for those with no high-risk features, the 
NNT was 113.
DISCUSSION
The 4 most important findings of our analysis of the 
COMPASS trial are as follows:
(1)  The lower rate of NCB adverse events with rivar-
oxaban 2.5 mg twice daily plus ASA versus ASA 
monotherapy was primarily driven by a reduction 
in “efficacy” events, whereas the increased risk 
in severe bleedings was markedly less frequent.
(2)  The lower rate of NCB adverse events became 
more pronounced with increasing follow-up 
duration as risk of bleeding was front loaded, 







Age, y 68.2±7.9 69.3±8.7 <0.0001
Female sex 3848 (22.2) 200 (20.7) 0.27
Body mass index, kg/m2 28.3±4.7 28.6±5.0 0.17
Systolic blood pressure, mm Hg 136±17 138±19 <0.0001
Diastolic blood pressure, mm Hg 78±10 78±11 0.50
Total cholesterol, mmol/L 4.2±1.1 4.3±1.1 0.0004
Tobacco use
  Never 5535 (32.0) 290 (30.1) 0.21
  Former 8083 (46.7) 454 (47.0) 0.83
  Current 3695 (21.3) 221 (22.9) 0.25
Hypertension 12 987 (75.0) 797 (82.6) <0.0001
Diabetes mellitus 6460 (37.3) 462 (47.9) <0.0001
Previous stroke 621 (3.6) 65 (6.7) <0.0001
Previous myocardial infarction 10 744 (62.1) 631 (65.4) 0.04
Heart failure 3661 (21.1) 281 (29.1) <0.0001
Coronary artery disease 15 688 (90.6) 886 (91.8) 0.21
Peripheral arterial disease 4671 (27.0) 325 (33.7) <0.0001
Estimated GFR
  <30 mL/min 144 (0.8) 19 (2.0) 0.0003
  30 to <60 mL/min 3689 (21.3) 316 (32.7) <0.0001
  ≥60 mL/min 13 476 (77.9) 630 (65.3) <0.0001
Race
  White 10 759 (62.1) 596 (61.8) 0.81
  Black 158 (0.9) 10 (1.0) 0.70
  Asian 2688 (15.5) 160 (16.6) 0.38
  Other 3708 (21.4) 199 (20.6) 0.56
Geographic region
  North America 2451 (14.2) 162 (16.8) 0.02
  South America 3894 (22.5) 214 (22.2) 0.82
  Western Europe, Israel, 
Australia, or South Africa
5420 (31.3) 290 (30.1) 0.41
  Eastern Europe 3055 (17.6) 156 (16.2) 0.24
  Asia-Pacific 2493 (14.4) 143 (14.8) 0.72
Medication
  ACE inhibitor or ARB 12 225 (70.6) 712 (73.8) 0.04
  Calcium-channel blocker 4606 (26.6) 289 (29.9) 0.02
  Diuretic 5107 (29.5) 366 (37.9) <0.0001
  Beta blocker 12 071 (69.7) 712 (73.8) 0.007
  Lipid-lowering agent 15 567 (89.9) 830 (86.0) 0.0001
  Nonsteroidal anti-inflammatory 
drugs
941 (5.4) 63 (6.5) 0.15
  Nonstudy proton pump inhibitor 6187 (35.7) 345 (35.8) 0.99
For continuous variables, plus-minus values are mean±SD. For categorical 
variables, frequency (%) are shown. P value is from the Wilcoxon 2-sample 
test for continuous variables, and Pearson χ2 test for categorical variables. ACE 
indicates angiotensin converting enzyme; ARB, angiotensin receptor blocker; 
GFR, glomerular filtration rate; and NCB, net clinical benefit.
Figure 1. Cumulative incidence of the net clinical benefit outcome 
among participants receiving rivaroxaban 2.5 mg twice daily plus 
aspirin or aspirin alone.
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whereas benefits in terms of reduction of cardio-
vascular disease events accrued throughout the 
treatment periods.
(3)  A higher ARR for NCB adverse outcomes was 
observed in the investigated high-risk subgroups, 
resulting in an even lower NNT.
(4)  Combining risk characteristics increased the ARR 
and increased the NCB.
NCB Analysis in COMPASS
Patients with “stable” coronary artery disease or PAD 
remain at a substantially increased long-term risk of car-
diovascular events.1 In the current European Society of 
Cardiology Guidelines, patients formerly termed to have 
“stable” coronary artery disease are now referred to as 
having “chronic coronary syndromes,” reflecting that 
these individuals are only stable in relative terms (com-
pared with immediately following an acute events such 
as MI) but remain at an increased risk of cardiovascular 
events over time.1 As such, prolonging an intensified 
anticoagulant regimen (such as by adding rivaroxaban 
2.5 mg twice daily to low-dose ASA) has been given 
a class IIa and IIb indication for patients at severe and 
moderate risk of recurrent events, respectively.1 Indeed, 
the addition of rivaroxaban 2.5 mg twice daily to ASA 
monotherapy has been shown in the COMPASS trial 
to reduce the risk of the composite of MI, stroke, and 
cardiovascular death by 24%. Conversely, however, a 
70% relative increase in the broad definition of “major 
bleeding” events was observed. In consequence, there 
is the perception that the risks of adding rivaroxaban 
2.5 mg twice daily may counterweigh the benefits. To 
put these findings into context, a more detailed analysis 
is required as a more inclusive definition of major bleed-
ing was used in COMPASS than in other trials of anti-
thrombotic therapy. The ISTH major bleeding definition 
(fatal bleeding, symptomatic bleeding into a critical area 
or organ, bleeding causing a decrease in the hemoglo-
bin level of ≥2 g/dL, or bleeding that led to transfusion 
of ≥2 U of whole blood or red cells)  was adapted for 
the COMPASS trial in response to regulators’ requests 
so that the modified ISTH definition also included any 
bleeding that resulted in hospitalization (with or with-
out overnight stay), and did not require a drop in he-
moglobin or transfusion. As such, major bleeding rates 
were about one-third more frequent than with the 
original ISTH definition, and many “major” bleedings 
occurring in COMPASS would not have been consid-
ered “major” bleedings in other large outcome trials.8 
This is of critical importance as the main driver of the 
70% increase in major bleeding observed in the trial 
were bleedings that led to presentation to an acute care 
facility or hospitalization,2,8 whereas the incidence of 
more severe bleeding events (ie, fatal or nonfatal symp-
tomatic bleedings into critical organs) was low and not 
different between the 2 treatment arms. A “top-line” 
comparison of the reduction in the composite primary 
efficacy end point versus the increase in the principal 
safety end point therefore has many important short-
comings mainly related to the mismatch in the clinical 
significance of included efficacy and bleeding events.
The predefined NCB offers 2 important advantages 
over separate assessment of efficacy and safety end 
points. First, it only encompasses the most severe “ef-
ficacy” and “safety” events (ie, MI, stroke, and cardio-
vascular death as well as fatal bleeding and symptomat-
ic bleeding into a critical organ). As a result, NCB rates 
are not diluted by events of lesser severity but instead 
represent a selection of outcomes with serious clinical 
consequences. Second, the inclusion of these events 
into 1 composite outcome ensures that each patient is 
only counted once even if they have multiple events and 
also allows for an easy and comprehensive assessment 
Table 2. Event Rates of the Net Clinical Benefit Outcome and Its Components
Rivaroxaban Plus Aspirin 
(N=9152) Aspirin Alone (N=9126)
Rivaroxaban Plus Aspirin vs. 
Aspirin Alone
Absolute Risk* 
Reduction (95% CI), 
Events Prevented/
Caused, per 1000 
Patients at 30 mo
NNT*/ 
NNH











(95% CI) P Value
Net clinical benefit 
outcome
431/9152 (4.7) 2.5 534/9126 (5.9) 3.1 0.80 (0.70–0.91) 0.0005 –19.5 (–28.9 to –10.0) 52
Cardiovascular death 160/9152 (1.7) 0.9 203/9126 (2.2) 1.2 0.78 (0.64–0.96) 0.02 –8.2 (–14.2 to –2.2) 122
Stroke 83/9152 (0.9) 0.5 142/9126 (1.6) 0.8 0.58 (0.44–0.76) <0.0001 –10.6 (–15.6 to –5.6) 95
Myocardial infarction 178/9152 (1.9) 1.0 205/9126 (2.2) 1.2 0.86 (0.70–1.05) 0.14 –4.8 (–10.8 to 1.2) 209
Fatal bleeding 15/9152 (0.2) 0.09 10/9126 (0.1) 0.06 1.49 (0.67–3.33) 0.32 0.4 (–1.5 to 2.2) 2671
Symptomatic bleeding 
into critical organ
73/9152 (0.8) 0.4 53/9126 (0.6) 0.3 1.37 (0.96–1.95) 0.08 2.8 (–0.8 to 6.3) 362
Percent (%) is the proportion of patients with an outcome. Percent per year (%/y) is the rate per 100 patient-years of follow-up. All analyses were based on the 
time to a first event. Hazard ratios (95% CI) are from the stratified Cox proportional hazards regression models fit in the respective subgroup. P values are from the 
stratified log-rank test. NNH indicates number needed to harm; and NNT, number needed to treat.
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of the overall benefit of the new treatment regimen 
rather than having to separately compare event rates 
and HRs of several different end points. Although any 
bleeding event may have an impact on subsequent 
events, “symptomatic bleeding into a critical organ” 
was included in the NCB because such life-threatening 
bleedings have been associated with a >3-fold larger in-
crease in mortality than “major bleedings.”9 In contrast, 
the increase in modified ISTH major bleeding events in 
COMPASS meant that the majority of those bleeding 
events were neither fatal nor involved bleeding into a 
critical organ. This conclusion is strengthened by the 
18% reduction in all-cause mortality of rivaroxaban 2.5 
mg twice daily plus ASA over ASA monotherapy ob-
served in the overall trial.2
Contribution of Severe Ischemic and 
Bleeding Events to the NCB
Our current analysis indicates that the trial “efficacy” 
outcomes constituted the majority of events factoring 
into the NCB composite. In this analysis of bleeding 
Figure 2. Incidence of the net clinical benefit outcome components.
A, Cumulative incidence of the net clinical benefit outcome components among participants receiving rivaroxaban 2.5 mg twice daily plus aspirin or aspirin 
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events with the most important clinical impact (fatal 
or bleeding into a critical organ), the absolute event 
rates were lower and mostly not statistically different 
between the 2 treatment arms. As a result, the larger 
reduction of severe ischemic outcomes outweighed the 
increase in severe bleeding events.
Time Course of Events Contributing to 
NCB
The antithrombotic comparisons in the COMPASS trial 
were discontinued early on the advice of the data and 
safety monitoring board because of the finding of >4 
Figure 3. Cumulative incidence of the net clinical benefit outcome according to selected risk characteristics in participants receiving rivaroxaban 2.5 
mg twice daily plus aspirin or aspirin alone.
eGFR indicates estimated glomerular filtration rate.
Figure 4. Event rates of net clinical benefit outcome in selected high-risk subgroups.
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SDs of benefit in the primary efficacy outcome for ri-
varoxaban 2.5 mg twice daily plus ASA versus ASA.2 
However, the time course of safety and efficacy events 
differed.8 The excess in major bleeding events was con-
fined to the first year, whereas the benefits in efficacy 
events continued to separate over time.8 An increased 
bleeding risk early during initiation of anticoagulant or 
antiplatelet therapy is not uncommon and can be relat-
ed to an unmasking of a causal pathology.10–12 In con-
trast, the reduction in efficacy events was augmented 
over time, resulting in an increasingly favorable NCB for 
the combination of rivaroxaban 2.5 mg twice daily plus 
ASA.7 Thus, the early discontinuation of the trial under-
estimated the NCB over the longer term because of the 
weighting of bleeding events in the first year of the tri-
al. This is of relevant clinical importance, particularly for 
long-term and potentially lifelong treatment regimens 
such as those for chronic coronary syndromes or PAD.
NCB in High-Risk Populations
Selected high-risk patient populations derived a statisti-
cally similar NCB from the combination of rivaroxaban 2.5 
mg twice daily as compared with ASA monotherapy in 
relative terms, and this resulted in a higher ARR and an 
even lower NNT. As for the overall population, this ben-
efit was primarily driven by a reduction in efficacy events. 
These results are of particular importance as rivaroxaban 
2.5 mg twice daily plus ASA has the largest clinical ben-
efit in patients with combinations of high-risk features. 
Such patients may currently be excluded from additional 
antithrombotic therapies based on clinical overestimation 
of bleeding risks and the lack of clear evidence of NCB.
At the same time, however, although ischemic event 
rates were lower in lower-risk patients, also these indi-
viduals are at considerable residual risk and should benefit 
from the combination of rivaroxaban 2.5 mg twice daily 
and ASA over the midterm to longer term. Indeed, also in 
these patients, the NCB became more favorable over time.
Limitations
Patients at sufficiently high risk of bleeding to preclude 
more intensive antithrombotic therapy were excluded 
from the COMPASS trial; as such, our findings cannot be 
extrapolated to patients with an exclusion for antithrom-
botic therapy. This analysis of NCB may underestimate 
potential longer-term benefits of this therapy because the 
early termination of the COMPASS trial results in greater 
weighting of early bleeding events in the analysis of NCB.
Conclusions
The lower rate in NCB adverse events through the ad-
dition of rivaroxaban 2.5 mg twice daily to ASA was 
primarily driven by a reduction in severe efficacy events, 
particularly stroke and cardiovascular mortality, whereas 
severe bleeding events were less frequent and had less 
impact. The excess in major and severe bleeding events 
was mainly confined to the first year of treatment in the 
trial. The NCB was increasingly favorable with increas-
ing study duration, and even more pronounced in high-
risk patient subgroups, particularly with combinations 
of risk characteristics. The NCB of rivaroxaban 2.5 mg 
twice daily plus ASA may hence represent an easy-to-
use metric to comprehensively estimate the overall ben-
efit of this treatment regimen in patients with chronic 
coronary syndromes and/or peripheral artery disease.
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